Full metadata record
DC FieldValueLanguage
dc.creatorMoreno-Viguri, E. (Elsa)-
dc.creatorJimenez-Montes, C. (Carmen)-
dc.creatorMartin-Escolano, R. (Ruben)-
dc.creatorSantivañez-Veliz, M. (Mery)-
dc.creatorMartin-Montes, A.(Alvaro)-
dc.creatorAzqueta, A. (Amaya)-
dc.creatorJimenez-Lopez, M. (Marina)-
dc.creatorZamora-Ledesma, S. (Salvador)-
dc.creatorCirauqui, N. (Nuria)-
dc.creatorLopez-de-Cerain, A. (Adela)-
dc.creatorMarin, C. (Clotilde)-
dc.creatorSanchez-Moreno, J.M. (José Manuel)-
dc.creatorPérez-Silanes, S. (Silvia)-
dc.identifier.citationMoreno-Viguri, E. (Elsa); Jimenez-Montes, C. (Carmen); Martin-Escolano, R. (Ruben); et al. "In vitro and in vivo anti-Trypanosoma cruzi activity of new arylamine Mannich base-type derivatives". J. Med. Chem. 24 (59), 2016, 10929 - 10945es_ES
dc.description.abstractChagas disease is a neglected tropical disease with 6-7 million people infected worldwide and there is no effective treatment. Therefore, there is an urgent need to continue researching in order to discover novel therapeutic alternatives. We present a series of arylaminoketone derivatives as means of identifying new drugs to treat Chagas disease in the acute phase with greater activity, less toxicity and with a larger spectrum of action than that corresponding to the reference drug benznidazole. Indexes of high selectivity found in vitro formed the basis for later in vivo assays in BALB/c mice. Murine model results show that compounds 3, 4, 7 and 10 induced a remarkable decrease in parasitemia levels in acute phase and the parasitemia reactivation following immunosuppression, and curative rates were higher than with benznidazole. These high anti-parasitic activities encourage us to propose these compounds as promising molecules for developing an easy to synthesize anti-Chagas agent.es_ES
dc.subjectMaterias Investigacion::Químicaes_ES
dc.titleIn vitro and in vivo anti-Trypanosoma cruzi activity of new arylamine Mannich base-type derivativeses_ES

Files in This Item:
720,27 kB
Adobe PDF

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.